MRNA therapy hopes to fix copper problem in wilson disease
NCT ID NCT07240896
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new mRNA drug called DSL101 in 18 adults with Wilson disease, a genetic condition that causes copper buildup. The drug is designed to help the body produce a protein that controls copper. Participants receive low, medium, or high doses by IV every four weeks. The main goal is to check safety, but researchers will also measure copper levels in urine and blood to see if the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DSL101 (ATP7B mRNA/LNP)
- What this could lead to
- If successful, this could point toward a treatment that helps the body manage copper levels, potentially reducing symptoms and complications of Wilson disease.
- What could go wrong
- This is a very early, small trial (18 people) focused on safety. It may not show clear benefit, and risks like infusion reactions or immune responses are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WILSONS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Anhui Medical University
RECRUITINGHefei, Anhui, 230000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.